Major Scope

  •  Colon and Rectal Surgery
  •  General Surgery
  •  Gynecologic Oncology
  •  Plastic Surgery
  •  Neurological Surgery
  •  Orthopaedic Surgery
  •  Orthopaedic Surgery of the Spine
  •  Neonatal Surgery
  •  Prenatal Surgery
  •  Trauma Surgery
  •  Surgical Intensivists, Specializing In Critical Care Patients
  •  Thoracic Surgery
  •  Congenital Cardiac Surgery
  •  Thoracic Surgery-Integrated
  •  Vascular Surgery

Abstract

Citation: Clin Surg. 2021;6(1):3212.Research Article | Open Access

A Prospective Study on the Role of Centchroman in Regression of Fibroadenoma

Navdeep Kumar Singla , Ruby Bhatia , Renu Verma and Suresh Kumar Bhatia

Department of General Surgery, GMC Patiala, Punjab, India Department of Obstetrics and Gynecology, GMC Patiala, Punjab, India

*Correspondance to: Renu Verma 

 PDF  Full Text DOI: 10.25107/2474-1647.3212

Abstract

Fibroadenoma commonly present as painless breast lump in young girls. Nearly 10% to 15% regress spontaneously over the period of 6 to 60 months, rest are managed surgically. Centchroman (Saheli), a novel non-steroidal, selective anti-estrogen has been used for the treatment of mastalgia and its effectiveness in the treatment of fibroadenoma is being tested in the ongoing trials. Patients and Methods: We studied the role of Centchroman in regression of fibroadenoma. A total of 60 patients between 15 to 35 years of age with painless lump breast of size 2 cm to 5 cm confirmed as fibroadenoma by FNAC were included in the study. Detailed patient?s characteristics, clinical history, physical examination (for size in 2 dimensions), ultrasound findings (for size in 3 dimensions) were assessed. All participants included in the study were given tablet Centchroman (Saheli) 30 mg thrice weekly orally for 3 months. Size of Fibroadenoma was reassessed clinically for size in two dimensions and ultrasonologically for size in three dimensions at 4 weeks and 3 months of starting of therapy. Conclusion: Out of 60 patients, 18 patients (30%) had complete response, 40 patients (66.66%) showed a decrease in the size of fibroadenoma and only 2 patients (3.33%) had no response to this therapy. None showed an increase in size. It may prove to be the most effective modality for the treatment of small sized fibroadenoma breast especially in unmarried girls with minimal side effects. Ultrasonology may be relied upon for follow up measurements since it is more accurate in measuring the dimensions.

Keywords

Fibroadenoma; Centchroman; Saheli; Non-steroidal; Anti-estrogen; Ultrasonology

Cite the article

Singla NK, Bhatia R, Verma R, Bhatia SK. A Prospective Study on the Role of Centchroman in Regression of Fibroadenoma. Clin Surg. 2021; 6: 3212..

Journal Basic Info

  • Impact Factor: 2.395**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
  • NLM ID: 101702548

Search Our Journal

Journal Indexed In

Articles in PubMed

Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
Mesh Sprayer Device with Liquefied Mesh Delivery System: Proposed Alternative for Currently Available Meshes in Hernia Repair and Supplement to Abdominal Closure
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Use of Accessible Blood Filter for Postoperative Cell Salvage in Cardiac Surgery
 Abstract  PDF  Full Text
Clinical Effects of Using the Enhanced Recovery after Surgery (ERAS) Approach on Postoperative Bariatric Surgery Status: A Review Study
 Abstract  PDF  Full Text
View More...